Phase I Open-Label Evaluation of CLN-978 in Patients with Treatment-Refractory Rheumatoid Arthritis

The primary objective of this study is to evaluate the safety and tolerability of **CLN-978** in patients with **treatment-refractory rheumatoid arthritis**. This is clinically relevant as it addresses the need for new therapeutic options in patients who do not respond to existing treatments, potentially improving patient outcomes and quality of life.

The clinical trial involves participants diagnosed with **Treatment-Refractory Rheumatoid Arthritis**. The study population includes both male and female subjects, encompassing an age range that includes adults and older adults. The trial population selection criteria and the total number of participants have not been disclosed by the sponsor. The study considers a vulnerable population, although specific lifestyle considerations such as diet, physical activity, or habits have not been detailed. The trial does not specify key inclusion or exclusion criteria, and the main objective of the trial remains unspecified.

The clinical trial is designed as a **Phase I, open-label study** to evaluate the investigational product CLN-978 in patients diagnosed with **treatment-refractory rheumatoid arthritis**. The trial is scheduled to commence on April 16, 2025, with an estimated completion date of July 27, 2029. The study will involve a series of structured visits, beginning with an inclusion visit, where participants will undergo screening to confirm eligibility based on predefined criteria. This initial visit will ensure that only suitable candidates are enrolled in the trial.

Following the inclusion visit, participants will attend regular follow-up visits throughout the study duration. These visits are crucial for monitoring the safety and efficacy of the investigational product, as well as for collecting data on any adverse events or changes in the participants' condition. The trial will conclude with an end-of-study visit, where final assessments will be conducted to evaluate the overall outcomes of the treatment.

The expected length of participant involvement in the trial will span the entire study period, from the initial screening to the end-of-study visit. However, certain conditions may necessitate early termination from the study, such as the occurrence of significant adverse events, withdrawal of consent by the participant, or any other medical or ethical reasons deemed appropriate by the study investigators. The trial's methodology and design are structured to ensure the collection of reliable and valid data, contributing to the understanding of the investigational product's potential benefits and risks in the target patient population.

The clinical trial documentation does not provide specific details regarding the experimental medication, including its name, pharmaceutical form, dosage, route, and frequency of administration. As such, no detailed description of the experimental treatment can be provided based on the available data.

Similarly, there is no information available about any non-experimental treatments used in the study, such as standard-of-care therapy, placebo, or comparator treatment. Consequently, no description of these treatments can be included.

Additional relevant information about drug administration, dosing schedules, and participant compliance monitoring is also not provided in the source data. Therefore, no further details can be offered regarding these aspects of the clinical trial.

The clinical trial is designed to assess efficacy in a Phase 3 study, with an estimated recruitment start date of April 16, 2025, and an estimated end date of July 27, 2029. The trial will focus on evaluating the efficacy of the investigational product, although specific parameters or endpoints for efficacy assessment are not detailed in the available data. The trial will adhere to rigorous standards typical of Phase 3 studies, ensuring that efficacy is measured accurately and reliably. The methods and schedule for measuring, collecting, and analyzing efficacy parameters are not specified, but they will likely involve validated scales, laboratory tests, or patient-reported outcomes, as is standard in clinical trials of this nature. The trial will be conducted in accordance with established clinical trial protocols to ensure the integrity and validity of the efficacy data collected.